Medicare Archives - Appy Medical

Continuous Glucose Monitors (CGMs) have revolutionized diabetes management by providing real-time insights into blood glucose levels. Understanding Medicare’s coverage for these devices is essential for beneficiaries seeking to optimize their diabetes care.

Medicare Coverage for CGMs

Medicare Part B classifies both therapeutic and non-therapeutic CGMs as durable medical equipment (DME), making them eligible for coverage¹. Medicare’s coverage extends to CGMs that meet specific criteria to ensure they are medically necessary and beneficial for managing diabetes².

Eligibility Criteria

To qualify for CGM coverage under Medicare, beneficiaries must:

Have Diabetes Mellitus – A confirmed diagnosis of diabetes is required².
Insulin Treatment – Beneficiaries must be on an insulin regimen that necessitates frequent adjustments based on glucose readings².
Insulin Administration – Medicare requires that the beneficiary administer insulin at least three times daily or use an insulin pump².
Self-Monitoring – Historically, Medicare required beneficiaries to monitor blood glucose levels at least four times daily using fingerstick tests³.
Medical Consultations – Beneficiaries must have in-person consultations with a healthcare provider every six months to assess adherence to the CGM regimen and overall diabetes management plan³.

Recent Policy Updates

As of July 1, 2022, Medicare mandates that all CGMs billed under Healthcare Common Procedure Coding System (HCPCS) codes E2102 and E2103 undergo review by the Pricing, Data Analysis, and Coding (PDAC) contractor. These devices must be listed on the Product Classification List (PCL) to ensure correct coding and eligibility for coverage⁴.

Coverage Limitations

Medicare does not cover CGMs intended solely for short-term diagnostic use, typically ranging from 72 hours to one week⁴.

Reimbursement Details

Medicare provides reimbursement for CGM-related services, with rates varying based on specific procedures and services rendered³. Proper documentation is crucial—while Medicare previously required evidence of at least four daily blood glucose tests to qualify for CGM coverage, this posed challenges since Medicare typically covered only three test strips per day for insulin-treated beneficiaries³.

Additionally, ensuring that the CGM device is correctly coded and listed on the PDAC’s Product Classification List is essential to avoid claim denials⁴.

2023 Update

In 2023, Medicare made significant changes to CGM coverage. Notably, the requirement for frequent fingerstick testing was removed, and coverage was expanded to include individuals with a history of problematic hypoglycemia, even if they are not on insulin therapy⁵.

As of April 16, 2023, Medicare now covers CGMs for beneficiaries who:

Have a confirmed diagnosis of diabetes mellitus⁵.
Are on any insulin regimen, without requiring a minimum frequency of injections⁵.
Have experienced severe hypoglycemia in the past, even if they are not on insulin therapy⁵.
Continue to meet medical consultation requirements, with regular in-person or telehealth visits with a healthcare provider⁵.

These updates aim to enhance access to CGMs, improving diabetes management for a broader group of beneficiaries⁵.

Conclusion

Medicare’s coverage for CGMs offers beneficiaries advanced tools for effective diabetes management. By understanding the eligibility criteria, staying updated on policy changes, and ensuring proper documentation, beneficiaries can maximize the benefits of CGM technology.

Disclaimer: Medicare policies and coverage criteria are subject to change. For the most current information, consult the official Medicare website (medicare.gov) or speak directly with a Medicare representative.